| 2026-04-16 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function tizianalifesciences.com ↗ |
| 2026-04-01 |
Tiziana Life Sciences LTD |
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging tizianalifesciences.com ↗ |
| 2025-09-15 |
Tiziana Life Sciences LTD |
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury tizianalifesciences.com ↗ |
| 2025-02-27 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury tizianalifesciences.com ↗ |
| 2025-01-23 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 tizianalifesciences.com ↗ |
| 2025-01-10 |
Tiziana Life Sciences LTD |
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 tizianalifesciences.com ↗ |
| 2024-10-30 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study tizianalifesciences.com ↗ |
| 2024-09-19 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease tizianalifesciences.com ↗ |
| 2024-04-19 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® tizianalifesciences.com ↗ |
| 2024-03-05 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease tizianalifesciences.com ↗ |
| 2024-01-05 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity- Associated Inflammation tizianalifesciences.com ↗ |
| 2023-04-27 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference tizianalifesciences.com ↗ |
| 2023-04-04 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference tizianalifesciences.com ↗ |
| 2023-04-04 |
Tiziana Life Sciences LTD |
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage tizianalifesciences.com ↗ |
| 2023-03-31 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference tizianalifesciences.com ↗ |
| 2022-09-15 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis tizianalifesciences.com ↗ |
| 2022-08-01 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease tizianalifesciences.com ↗ |
| 2022-03-25 |
Tiziana Life Sciences LTD |
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody tizianalifesciences.com ↗ |
| 2022-03-10 |
Tiziana Life Sciences LTD |
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody tizianalifesciences.com ↗ |
| 2022-02-04 |
Tiziana Life Sciences LTD |
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease tizianalifesciences.com ↗ |
| 2021-09-07 |
Tiziana Life Sciences LTD |
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment tizianalifesciences.com ↗ |
| 2021-09-02 |
Tiziana Life Sciences LTD |
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment tizianalifesciences.com ↗ |
| 2021-09-02 |
Precision BioSciences, Inc. |
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment precisionbiosciences.com ↗ |
| 2021-08-17 |
Tiziana Life Sciences LTD |
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil tizianalifesciences.com ↗ |
| 2021-06-23 |
Tiziana Life Sciences LTD |
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody tizianalifesciences.com ↗ |
| 2021-05-25 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Progr tizianalifesciences.com ↗ |
| 2021-03-30 |
Tiziana Life Sciences LTD |
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody tizianalifesciences.com ↗ |
| 2021-03-30 |
Tiziana Life Sciences LTD |
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program tizianalifesciences.com ↗ |
| 2021-02-02 |
Tiziana Life Sciences LTD |
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil tizianalifesciences.com ↗ |
| 2021-01-04 |
Tiziana Life Sciences LTD |
Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil tizianalifesciences.com ↗ |
| 2020-11-02 |
Tiziana Life Sciences LTD |
Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody tizianalifesciences.com ↗ |
| 2020-09-17 |
Tiziana Life Sciences LTD |
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil tizianalifesciences.com ↗ |
| 2020-08-18 |
Tiziana Life Sciences LTD |
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease tizianalifesciences.com ↗ |
| 2020-07-31 |
Tiziana Life Sciences LTD |
Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients tizianalifesciences.com ↗ |
| 2020-07-16 |
Tiziana Life Sciences LTD |
Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy tizianalifesciences.com ↗ |
| 2020-06-04 |
Tiziana Life Sciences LTD |
Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease tizianalifesciences.com ↗ |
| 2020-01-09 |
Tiziana Life Sciences LTD |
Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers tizianalifesciences.com ↗ |
| 2019-12-04 |
Tiziana Life Sciences LTD |
Tiziana Announces Initiation of a Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers tizianalifesciences.com ↗ |
| 2019-10-31 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA irasia.com ↗ |
| 2019-09-02 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
VOLUNTARY ANNOUNCEMENT - RECOMBINANT ANTI-HER2 AND ANTI-CD3 HUMANIZED BISPECIFIC ANTIBODY FOR INJECTION WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA irasia.com ↗ |
| 2019-07-01 |
Tiziana Life Sciences LTD |
Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes tizianalifesciences.com ↗ |
| 2019-06-24 |
Tiziana Life Sciences LTD |
Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform tizianalifesciences.com ↗ |
| 2018-11-28 |
Tiziana Life Sciences LTD |
Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers tizianalifesciences.com ↗ |
| 2018-03-16 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT ANTI-EpCAM AND ANTI-CD3 HUMAN-MOUSE CHIMERIC BISPECIFIC ANTIBODY FOR INJECTION" WAS GRANTED DRUG CLINICAL TRIAL APPROVAL irasia.com ↗ |
| 2007-01-03 |
MacroGenics |
MacroGenics and JDRF Form Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes macrogenics.com ↗ |
| 1996-09-01 |
7 Hills Pharma, LLC |
Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation 7hillspharma.com ↗ |
|